'Rare outliers': Feng Zhang eyes a new path to genetic medicine delivery with ex-Alnylam leaders and $193M
Marquee CRISPR scientist Feng Zhang, two-decade Alnylam oncology head Akin Akinc and seasoned biotech guru John Maraganore have come together for a new bet on gene editing, aiming to go beyond the scope of the existing crop of clinical-stage tools.
They hope to deliver big time — attempting to upend where potential therapeutic gold mines can go in the body, how they get shuttled and the types of diseases the long-hyped genetic medicine field can treat.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.